WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407126

CAS#: 146135-18-4

Description: GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X displayed activity in vivo against NUT-midline carcinoma, multiple myeloma, mixed-lineage leukemia, and acute myeloid leukemia. Bromodomain and extra-terminal (BET) proteins belong to a class of proteins collectively called epigenetic "readers". BET bromodomains have emerged as promising drug targets for treatment of cancers, inflammatory diseases, and other medical conditions.

Chemical Structure

CAS# 146135-18-4

Theoretical Analysis

MedKoo Cat#: 407126
Name: GW-841819X
CAS#: 146135-18-4
Chemical Formula: C26H22ClN5O3
Exact Mass: 487.14112
Molecular Weight: 487.94
Elemental Analysis: C, 64.00; H, 4.54; Cl, 7.27; N, 14.35; O, 9.84

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-01. Prices are subject to change without notice.

GW-841819X is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Synonym: GW-841819X; GW841819X; GW 841819X; GW 841819; GW841819; GW-841819.

IUPAC/Chemical Name: benzyl (R)-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)carbamate


InChi Code: InChI=1S/C26H22ClN5O3/c1-16-30-31-25-24(29-26(33)35-15-17-6-4-3-5-7-17)28-23(18-8-10-19(27)11-9-18)21-14-20(34-2)12-13-22(21)32(16)25/h3-14,24H,15H2,1-2H3,(H,29,33)/t24-/m0/s1

SMILES Code: O=C(OCC1=CC=CC=C1)N[C@H]2C3=NN=C(C)N3C4=CC=C(OC)C=C4C(C5=CC=C(Cl)C=C5)=N2

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 487.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Bamborough, P. and C.-W. Chung Screening inhibitors of human BRD-2 to 4 bromodomains binding to acetylated lysine residues of their physiol. partner proteins: 66pp.

Baud, M. G. J., E. Lin-Shiao, et al. "A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes." Science (Washington, DC, U. S.) 346(6209): 638-641.

Chung, C.-w., H. Coste, et al. "Discovery and characterization of small molecule inhibitors of the BET family bromodomains." J. Med. Chem. 54(11): 3827-3838.

Crowe, M., A. C.-M. Daugan, et al. Condensed azepine derivatives as bromodomain inhibitors and their preparation and use in the treatment of cancer, chronic autoimmune and inflammatory diseases: 109pp.

Finkel, T. H., J. Wang, et al. Compositions and methods comprising bromodomain (BET) antagonists for the treatment of HIV infection: 37pp.

Finkel, T. H., J. Wang, et al. Compositions and methods for the treatment of HIV infection using a bromodomain and extra-terminal (BET) protein antagonist: 27 pp., Cont.-in-part of Appl. No. PCT/US2012/048809.

Freidinger, R. M., B. E. Evans, et al. (1992). Preparation of triazolobenzodiazepines as CCK and gastrin antagonists: 93 pp.

Mirguet, O., R. Gosmini, et al. "Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains." J. Med. Chem. 56(19): 7501-7515.

Ursu, A. and H. Waldmann "Hide and seek: Identification and confirmation of small molecule protein targets." Bioorg. Med. Chem. Lett. 25(16): 3079-3086.

Zhao, Y., C.-Y. Yang, et al. "The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development." J. Med. Chem. 56(19): 7498-7500.


10mg / Not available